300 related articles for article (PubMed ID: 26873688)
1. Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure.
Nichols CI; Vose JG; Mittal S
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873688
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a risk-stratified approach to cardiac resynchronisation therapy defibrillators (high versus low) at the time of generator change.
Claridge S; Sebag FA; Fearn S; Behar JM; Porter B; Jackson T; Sieniewicz B; Gould J; Webb J; Chen Z; O'Neill M; Gill J; Leclercq C; Rinaldi CA
Heart; 2018 Mar; 104(5):416-422. PubMed ID: 28970277
[TBL] [Abstract][Full Text] [Related]
3. The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.
Landolina M; Morani G; Curnis A; Vado A; D'Onofrio A; Bianchi V; Stabile G; Crosato M; Petracci B; Ceriotti C; Bontempi L; Morosato M; Ballari GP; Gasparini M
Europace; 2017 Aug; 19(8):1349-1356. PubMed ID: 27702861
[TBL] [Abstract][Full Text] [Related]
4. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
[TBL] [Abstract][Full Text] [Related]
5. Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort.
Varma N; Mittal S; Prillinger JB; Snell J; Dalal N; Piccini JP
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28490521
[TBL] [Abstract][Full Text] [Related]
6. Implementation and reimbursement of remote monitoring for cardiac implantable electronic devices in Europe: a survey from the health economics committee of the European Heart Rhythm Association.
Mairesse GH; Braunschweig F; Klersy K; Cowie MR; Leyva F
Europace; 2015 May; 17(5):814-8. PubMed ID: 25713012
[TBL] [Abstract][Full Text] [Related]
7. Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study.
Clémenty N; Carion PL; Léotoing L; Lamarsalle L; Wilquin-Bequet F; Brown B; Verhees KJP; Fernandes J; Deharo JC
Europace; 2018 Dec; 20(12):1974-1980. PubMed ID: 29672690
[TBL] [Abstract][Full Text] [Related]
8. Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA.
Boriani G; Merino J; Wright DJ; Gadler F; Schaer B; Landolina M
Europace; 2018 Dec; 20(12):1882-1897. PubMed ID: 29757390
[TBL] [Abstract][Full Text] [Related]
9. Management of functional Sprint Fidelis leads at cardiac resynchronization therapy-defibrillator generator replacement: a novel option for preventing inappropriate shocks from lead failure in fragile patients with high risk of sudden death.
Zhu DWX; Chu MM; House CM
Europace; 2017 Dec; 19(12):2007-2014. PubMed ID: 27940933
[TBL] [Abstract][Full Text] [Related]
10. Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States.
Patel N; Viles-Gonzalez J; Agnihotri K; Arora S; Patel NJ; Aneja E; Shah M; Badheka AO; Pothineni NV; Kancharla K; Mulpuru S; Noseworthy PA; Kusumoto F; Cha YM; Deshmukh AJ
J Cardiovasc Electrophysiol; 2018 Oct; 29(10):1425-1435. PubMed ID: 30016005
[TBL] [Abstract][Full Text] [Related]
11. Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in Italy.
Palmisano P; Accogli M; Zaccaria M; Luzzi G; Nacci F; Anaclerio M; Favale S
Europace; 2013 Apr; 15(4):531-40. PubMed ID: 23407627
[TBL] [Abstract][Full Text] [Related]
12. Infective endocarditis and risk of death after cardiac implantable electronic device implantation: a nationwide cohort study.
Özcan C; Raunsø J; Lamberts M; Køber L; Lindhardt TB; Bruun NE; Laursen ML; Torp-Pedersen C; Gislason GH; Hansen ML
Europace; 2017 Jun; 19(6):1007-1014. PubMed ID: 28073883
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.
Mealing S; Woods B; Hawkins N; Cowie MR; Plummer CJ; Abraham WT; Beshai JF; Klein H; Sculpher M
Heart; 2016 Nov; 102(21):1742-1749. PubMed ID: 27411837
[TBL] [Abstract][Full Text] [Related]
14. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors and Temporal Trends of Complications Associated With Transvenous Implantable Cardiac Defibrillator Leads.
Koneru JN; Jones PW; Hammill EF; Wold N; Ellenbogen KA
J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29748177
[TBL] [Abstract][Full Text] [Related]
16. Developing a crush: acute implantable cardioverter-defibrillator lead insulation break in a patient with multiple leads.
Tilling L; Mason M
Europace; 2014 Aug; 16(8):1196. PubMed ID: 25074973
[No Abstract] [Full Text] [Related]
17. Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.
Lunati M; Proclemer A; Boriani G; Landolina M; Locati E; Rordorf R; Daleffe E; Ricci RP; Catanzariti D; Tomasi L; Gulizia M; Baccillieri MS; Molon G; Gasparini M;
Europace; 2016 Sep; 18(9):1391-8. PubMed ID: 26826135
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Utilization and Expenditures Associated With Appropriate and Inappropriate Implantable Defibrillator Shocks.
Turakhia MP; Zweibel S; Swain AL; Mollenkopf SA; Reynolds MR
Circ Cardiovasc Qual Outcomes; 2017 Feb; 10(2):. PubMed ID: 28196927
[TBL] [Abstract][Full Text] [Related]
19. REPLACE DARE (Death After Replacement Evaluation) score: determinants of all-cause mortality after implantable device replacement or upgrade from the REPLACE registry.
Chung MK; Holcomb RG; Mittal S; Steinberg JS; Gleva MJ; Mela T; Uslan DZ; Mitchell K; Poole JE;
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1048-56. PubMed ID: 25221331
[TBL] [Abstract][Full Text] [Related]
20. Increased late complex device infections are determined by cardiac resynchronization therapy-defibrillator infection.
Unsworth JD; Zaidi A; Hargreaves MR
Europace; 2015 Nov; 17(11):1708-11. PubMed ID: 25883081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
